Professional interpretation of whether Upadacitinib is a hormonal drug

Upadacitinib is an oral selective Januskinase1(JAK1< span>) inhibitors, mainly by inhibiting the activity of JAK1 in the JAK-STAT signaling pathway, regulating the excessive inflammatory response of the immune system and achieving the purpose of treating autoimmune diseases. It is widely used in the treatment of moderate to severe rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis and other inflammatory diseases. It needs to be made clear that upadatinib is not a hormonal drug. It is a small molecule targeted immunomodulator that exerts its efficacy by precisely inhibiting the activity of specific enzymes, rather than the hormone replacement or hormone regulation mechanism used by hormonal drugs.

Hormonal drugs usually refer to glucocorticoids (such as prednisone, dexamethasone) and mineral corticosteroids, which mainly produce extensive anti-inflammatory and immunosuppressive effects by regulating gene expression and cell function. Although hormonal drugs can quickly control inflammation in the short term, long-term use is often associated with serious side effects, such as osteoporosis, diabetes, high blood pressure, and increased risk of infection. In contrast, upadatinib, as a JAK inhibitor, can more specifically regulate the immune response by blocking the inflammatory signaling pathway. Theoretically, its side effects are more controllable than hormone drugs and avoids hormone-related systemic metabolic abnormalities.

From a pharmacological perspective, upadatinib acts on the intracellular enzyme system, blocking the signaling of pro-inflammatory cytokines such as IL-6, IFN-γ, etc., reducing the release of inflammatory factors, thereby alleviating tissue damage and inflammatory symptoms. Its mechanism is different from that of hormone drugs that directly regulate nuclear receptors and gene transcription. It is one of the representatives of modern targeted therapy. In clinical practice, upadatinib is often used in patients who have insufficient response to traditional immunosuppressants or who wish to avoid long-term side effects of hormones. It is currently an effective option for the treatment of autoimmune diseases.

To sum up, upadatinib is not a hormonal drug, but a new type of JAK1 enzyme inhibitor with precise targeting and good safety characteristics. When patients receive upatinib treatment, they do not need to worry about side effects such as abnormal bone metabolism and hyperglycemia that are common with traditional hormonal drugs, but they still need to regularly monitor hematological indicators and infection risks under the guidance of professional doctors. Understanding the difference between it and hormonal drugs can help patients understand the drug scientifically and reasonably expect the treatment effect and safety.

Reference materials:https://www.drugs.com/